Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy
| Autor: | Robert L. Ashford, Mourad Labib, Jon H. Raphael, Rui V. Duarte, Andrew Whallett, Jane L. Southall |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Pathology drug delivery systems implantable Bone density Osteoporosis Anaesthesia Follicle-stimulating hormone Sex hormone-binding globulin Internal medicine hypogonadism Medicine Bone mineral biology business.industry Research Chronic pain bone density Testosterone (patch) General Medicine medicine.disease Opioid biology.protein chronic pain business medicine.drug |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2013-002856 |
| Popis: | Objectives This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopaenia and/or osteoporosis in those diagnosed with hypogonadism. Design Observational study using health data routinely collected for non-research purposes. Setting Department of Pain Management, Russells Hall Hospital, Dudley, UK. Patients Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculating the free testosterone level. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism. Results Based on the calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|